Phase I/II clinical trial of HLA-A24 restricted epitope peptide cocktail therapy with UFT+LV for patients with advanced metastatic colorectal cancer.

Phase I/II clinical trial of HLA-A24 restricted epitope peptide cocktail therapy with UFT+LV for patients with advanced metastatic colorectal cancer. - Peptide vaccine therapy with UFT+LV for patients with advanced metastatic colorectal cancer.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007801

Enrollment

Registered

2012-04-20

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced metastatic colorectal cancers

Interventions

Subcutaneous injection of cancer vaccine (seven peptides) UFT+LV

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Standard therapies failured metastatic colorectal cancers. 2 Performance status 0 - 2 3 More than 4 weeks after previous therapy. 4 WBC >= 2000, Platelet >= 50000, GOT GPT <= 150, T.bil <= 3, Cr <= 3 5 HLA-A24 positive 6 Informed consent

Exclusion criteria

Exclusion criteria: Pregnant Lactation Prognosis >= 3 months Active infectious disease Systemic use of steroid hormones or immunosuppressive drugs. Others (Doctors judges)

Design outcomes

Primary

Measure	Time frame
Safty Immunological response (in vitro CTL induction)	—

Secondary

Measure	Time frame
Progression free survival Overall survival Data related to tumor regression Tumor marker (CEA) profile	—

Countries

Japan

Contacts

Public ContactFumiaki Sugiura

Kinki University School of Medicine Department of Surgery

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026